ORTHOSERA GMBH

Their core work

Orthosera is an Austrian biotech SME that develops advanced 3D tissue engineering platforms — nanofibrous scaffolds, organotypic models, and bioreactor systems — for biomedical research and drug testing. Their work bridges scaffold fabrication techniques (electrospinning, 3D printing) with living cell systems, including induced pluripotent stem cells (iPSCs), to build functional tissue analogs that mimic real biological environments. They apply these platforms to two main problems: modeling and regenerating bone and cartilage tissue affected by osteoporosis and osteoarthritis, and testing how nanoparticles behave and accumulate across biological barriers (ADME). Their output is laboratory infrastructure that makes preclinical drug and toxicology testing more biologically predictive.

What they specialise in

How they've shifted over time

Both H2020 projects ran concurrently (2019–2024), so the keyword split reflects two parallel research tracks rather than a strict before/after timeline shift. The first track — iPSC-seeded scaffolds for musculoskeletal disease — centers on tissue regeneration and personalized medicine for ageing-related conditions. The second track — organotypic models for nanoparticle toxicology — extends the same scaffold and bioreactor know-how into drug safety testing, suggesting Orthosera is deliberately broadening from disease-specific tissue engineering toward platform tools usable across drug development and nanomaterial regulation.

Orthosera appears to be positioning itself as a provider of standardized 3D tissue testing platforms for the pharmaceutical and nanotechnology industries, extending beyond disease-specific research into broadly applicable preclinical screening infrastructure.

How they like to work

Orthosera has participated in both projects as a partner, never as coordinator — consistent with a specialist SME that brings technical manufacturing capabilities (scaffold production, bioreactor systems) to academically-led consortia. MSCA-RISE projects involve researcher exchange across partners, meaning Orthosera both sends and hosts visiting scientists, creating more intensive working relationships than standard project partnerships. With 15 distinct partners across 10 countries from only 2 projects, they operate in large, internationally diverse consortia where their role is to deliver specific experimental platforms rather than manage overall project direction.

Orthosera has built connections with 15 unique partners spanning 10 countries through just two MSCA-RISE consortia — broad reach for a company of this size. The RISE scheme's researcher mobility focus means these are hands-on working relationships, not just contractual ones.

What sets them apart

Orthosera occupies a rare overlap between scaffold fabrication engineering and living cell biology — they do not just make structures, they make structures that function with iPSCs, bioreactors, and biological barriers in ways that replicate real tissue. For a consortium builder, this offers a self-contained experimental platform capability: 3D scaffold design, cell loading protocol, and analytical readout in one SME partner. Their MSCA-RISE track record also makes them an established European node for researcher exchange in tissue engineering, which is attractive for projects that need to demonstrate international mobility and knowledge transfer.

Highlights from their portfolio

• iP-OSTEO
  The largest and most technically ambitious project (EUR 46,000), combining iPSC biology with active nanofibrous osteochondral scaffolds in a personalized medicine approach to osteoporosis and osteoarthritis — diseases affecting hundreds of millions globally.
• ActiTOX
  Demonstrates Orthosera's ability to pivot their scaffold platform into regulatory-relevant drug safety testing (ADME, nanoparticle toxicology), opening a clear commercial pathway toward pharmaceutical and nanomaterial industry clients.